Inactive Instrument

HEAH SCIE Stock

Equities

HSAQ

KYG4411D1097

Dynamic Chart
Insider Buy: Health Sciences Acquisitions Corp 2 MT
Health Sciences Acquisitions Corporation 2(NasdaqCM:HSAQ) dropped from NASDAQ Composite Index CI
Orchestra BioMed, Inc. completed the acquisition of Health Sciences Acquisitions Corporation 2 from HSAC 2 Holdings, LLC, RTW Investments, LP and others in a reverse merger transaction. CI
Health Sciences Acquisitions Corporation 2 Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Health Sciences Acquisitions Corporation 2 Auditor Raises 'Going Concern' Doubt CI
Health Sciences Acquisitions Corporation 2 Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Health Sciences Acquisitions Corporation 2 Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Insider Buy: Health Sciences Acquisitions Corp 2 MT
Orchestra BioMed, Health Sciences Acquisitions Corp. to Merge; Combined Company to be Listed on Nasdaq MT
Orchestra BioMed, Inc. entered into an agreement and plan of merger agreement to acquire Health Sciences Acquisitions Corporation 2 from HSAC 2 Holdings, LLC, RTW Investments, LP and others for $93 million. CI
Health Sciences Acquisitions Corporation 2 Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Health Sciences Acquisitions Corporation 2 Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Health Sciences Acquisitions Corporation 2 Auditor Raises 'Going Concern' Doubt CI
Health Sciences Acquisitions Corporation 2 Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Health Sciences Acquisitions Corporation 2 Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
More news
Health Sciences Acquisitions Corporation 2 is a blank check company. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. It intends to target companies domiciled in North America or Europe that are developing assets in the biopharma and medical technology sectors. It has generated no revenues.
Sector
-
More about the company